영상을 이용한 방사핵종 치료의 선량평가

키워드

참고문헌 (36)

1. Kramer-Marek G, "The role of nuclear medicine in modern therapy of cancer", Tumour Biol, 33(3), pp.629~640 (2012)
2. Klubo-Gwiezdzinska J, "Efficacy of dosimetric versus empiric prescribed activity of 131I for therapy of differentiated thyroid cancer", J Clin Endocrinol Metab, 96(10), pp.3217~3225 (2011)
3. Reilly RM, "Monoclonal antibody and peptide-targeted radiotherapy of cancer, In Dosimetry for targeted radiotherapy" (2010), John Wiley & Sons
4. Chung JK, "Koh chang-soon nuclear medicine" (2008), Korea Medical Science
5. Stabin MG, "MIRDOSE: personal computer software for internal dose assessment in nuclear medicine", J Nucl Med, 37(3), pp.538~546 (1996)
6. DeNardo SJ, "Radioimmunotherapy for breast cancer using indium-111", yttrium-90 BrE-3: results of a phase I clinical trial, 1997, pp.38(8), 1180~1185
7. Tsui BM, "Quantitative single-photon emission computed tomography: basics and clinical considerations", Semin Nucl Med, 24(1), pp.38~65 (1994)
8. Siegel JA, "MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates", J Nucl Med, 40(2), pp.37S~61S (1999)
9. Akbari RB, "Radionuclide purity and radiation dosimetry of 124I used in positron tomography of the thyroid", Phys Med Biol, 31(7), pp.789~791 (1986)
10. Flower MA, "Thyroid imaging using positron emission tomography--a comparison with ultrasound imaging and conventional scintigraphy in thyrotoxicosis", Br J Radiol, 63(749), pp.325~330 (1990)
11. Ott RJ, "Measurement of radiation dose to the thyroid using positron emission tomography", Br J Radiol, 60(711), pp.245~251 (1987)
12. Westera G, "Radioimmuno positron emission tomography with monoclonal antibodies: a new approach to quantifying in vivo tumour concentration and biodistribution for radioimmunotherapy", Nucl Med Commun, 12(5), pp.429~437 (1991)
13. Pentlow KS, "Quantitative imaging of I-124 using positron emission tomography with applications to radioimmunodiagnosis and radioimmunotherapy", Med Phys, 18(3), pp.357~366 (1991)
14. Larson SM, "PET scanning of iodine-124-3F9 as an approach to tumor dosimetry during treatment planning for radioimmunotherapy in a child with neuroblastoma", J Nucl Med, 33(11), pp.2020~2023 (1992)
15. Pentlow KS, "Quantitative imaging of iodine-124 with PET", J Nucl Med, 37(9), pp.1557~1562 (1996)
16. Lubberink M, "Positron emission tomography and radioimmunotargeting--aspects of quantification and dosimetry", Acta Oncol, 38(3), pp.343~349 (1999)
17. Sgouros G, "Three-dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancer", Eur J Nucl Med Mol Imaging, 38(Suppl 1), pp.S41~S$& (2011)
18. Helisch A, "Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours", Eur J Nucl Med Mol Imaging, 31(10), pp.1386~1392 (2004)
19. Barone R, "Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship", J Nucl Med, 46(Suppl 1), pp.99S~106S (2005)
20. Maxon HR, "Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer", N Engl J Med, 309(16), pp.937~941 (1983)
21. Maxon HR, "Dosimetric considerations in the radioiodine treatment of macrometastases and micrometastases from differentiated thyroid cancer", Thyroid, 7(2), pp.183~187 (1997)
22. Benua RS, "The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer", Am J Roentgenol Radium Ther Nucl Med, 87, pp.171~182 (1962)
23. Freudenberg LS, "Thyroid remnant dose: 124I-PET", CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer, 2010, pp.118(7), 393~399
24. O'Connell ME, "Radiation dose assessment in radioiodine therapy. Dose-response relationships in differentiated thyroid carcinoma using quantitative scanning and PET", Radiother Oncol, 28(1), pp.16~26 (1993)
25. Eschmann SM, "Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET", Eur J Nucl Med Mol Imaging, 29(6), pp.760~767 (2002)
26. Freudenberg LS, "124I-PET dosimetry in advanced differentiated thyroid cancer: therapeutic impact", Nuklearmedizin, 46(4), pp.121~128 (2007)
27. Im HJ, "Evaluation of surgical completeness in endoscopic thyroidectomy compared with open thyroidectomy with regard to remnant ablation", Clin Nucl Med, 37(2), pp.148~151 (2012)
28. Lim I, "Prognostic implication of thyroglobulin and quantified whole body scan after initial radioiodine therapy on early prediction of ablation and clinical response for the patients with differentiated thyroid cancer", Ann Nucl Med, 26(10), pp.777~786 (2012)
29. Schmitz G, "Expression of the sodium iodide symporter in differentiated thyroid cancer: clinical evidence", Nuklearmedizin, 44(3), pp.86~93 (2005)
30. Jentzen W, "Relationship between cumulative radiation dose and salivary gland uptake associated with radioiodine therapy of thyroid cancer", Nucl Med Commun, 27(8), pp.669~676 (2006)
31. Jentzen W, "Pre-therapeutic (124)I PET(", CT) dosimetry confirms low average absorbed doses per administered (131)I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer, 2010, pp.37(5), 884~895
32. Jentzen W, "The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET(", CT) imaging, 2010, pp.37(12), 2298~2306
33. Nakada K, "Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?", J Nucl Med, 46(2), pp.261~266 (2005)
34. 변병현, "반복적인 131I rituximab 방사면역치료를 시행 받은 비호지킨 림프종 환자 군에서 종양 부위의 영상기반 방사선 흡수선량 평가와 임상적 의의", Nuclear Medicine and Molecular Imaging, 43(1), pp.60~71 (2009), 대한핵의학회
35. Flux G, "The impact of PET and SPECT on dosimetry for targeted radionuclide therapy", Z Med Phys, 16(1), pp.47~59 (2006)
36. Freudenberg LS, "Clinical applications of 124I-PET", CT in patients with differentiated thyroid cancer, 2011, pp.38(Suppl 1), S48~S56

관련 논문AI추천